Phase I study of transforming growth factor-β3 mouthwashes for prevention of chemotherapy-induced mucositis

Clinical Cancer Research

Volumn 5, Issue 6, 1999, Pages 1363-1368

  Wymenga, A N Machteld ^a   Van Der Graaf, Winette T A ^a   Hofstra, Lieuwe S ^a   Spijkervet, Fred K L ^a   Timens, Wim ^a   Timmer Bosscha, Hetty ^a   Sluiter, Wim J ^a   Van Buuren, A H J A W ^b   Mulder, Nanno H ^a   De Vries, Elisabeth G E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Novartis Pharmaceuticals Corporation   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DRUG ANTIBODY; EPIRUBICIN; FLUOROURACIL; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA3; THIOTEPA; TRANSFORMING GROWTH FACTOR BETA3;

ADULT; ARTICLE; BREAST CANCER; CELL STRUCTURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG DOSAGE FORM; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MOUTH MUCOSA; MUCOSA INFLAMMATION; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; ANTIBODIES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MIDDLE AGED; MOUTH MUCOSA; MOUTHWASHES; STOMATITIS; TRANSFORMING GROWTH FACTOR BETA;

EID: 0033052122     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Hoekman, K., and Vermorken, J. B. Incidence and prevention of nonhaematological toxicity of high-dose chemotherapy. Ann. Med., 28: 175-182, 1996.
2. Rodenhuis, S., Westermann, A., Holtkamp, M. J., Nooijen, W. J., Baars, J. W., Van der Wall, E., Slaper-Cortenbach, I. C. M., and Schornagel, J. H. Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer. J. Clin. Oncol., 14: 1473-1383, 1996.
3. Peterson, D. E. Oral toxicity of chemotherapeutic agents. Semin. Oncol., 19: 478-491, 1992.
4. Loprinzi, C. L., Cianflone, S. G., Dose, A. M., Etzell, P. S., Burnham, N. L., Therneau, T. M., Hagen, L., Gainey, D. K., Cross, M., Athmann, L. M., Fischer T., and O'Connel, M. J. A controlled evaluation of an allopurinol mouthwash as prophylaxis against 5-fluorouracil-induced stomatitis. Cancer (Phila.), 65: 1879-1882, 1990.
5. Loprinzi, C. L., Ghosh, C., Camoriano, J., Sloan, J., Steen, P. D., Michalak, J. C., Schaefer, P. L., Novotny, P. J., Gerstner, J. B., White, D. F., Hatfield, A. K., and Quella, S. K. Phase III controlled evaluation of sucralfate to alleviate stomatitis in patients receiving fluorouracil-based chemotherapy. J. Clin. Oncol., 15: 1235-1238, 1997.
6. Rymes, N., Glick, L., and Holmes, J. A. Topical mesalazine in the treatment of chemotherapy and radiotherapy-induced oral mucositis. Bone Marrow Transplant., 18: 484, 1996.
7. Verdi, C. J., Garewal, H. S., Koenig, L. M., Vaughn, B., and Burkhead, T. A double-blind, randomized, placebo-controlled trial of pentoxifylline for the prevention of chemotherapy-induced oral mucositis. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod., 80: 36-42, 1995.
8. Skubitz, K. M., and Anderson, P. M. Oral glutamine to prevent chemotherapy induced stomatitis: a pilot study. J. Lab. Clin. Med., 127: 223-228, 1996.
9. Anderson, P. M., Ramsay, N. K. C., Shu, X. O., Rydholm, N., Rogosheske, J., Nicklow, R., Weisdorf, D. J., and Skubitz, K. M. Effect of low-dose oral glutamine on painful stomatitis during bone marrow transplantation. Bone Marrow Transplant., 22: 339-344, 1998.
10. Anderson, P. M., Schroeder, G., and Skubitz, K. M. Oral glutamine reduces the duration and severity of stomatitis after cytotoxic cancer chemotherapy. Cancer (Phila.), 83: 1433-1439, 1998.
11. Duenas-Gonzales, A., Sobrevilla-Calvo, P., Frias-Mendivil, M., Gallardo-Rincon, D., Lara-Medina, F., Aguilar-Ponce, L., Miranda-Lopez, E., Zinser-Sierra, J., and Reynoso-Gomez, E. Mistoprolol prophylaxis for high-dose chemotherapy-induced mucositis: a randomized double-blind study. Bone Marrow Transplant., 17: 809-812, 1996.
12. Sonis, S., Muska, A., O'Brien, J., VanVugt, A., Langer-Safer, P., and Keith, J. Alteration in the frequency, severity and duration of chemotherapy-induced mucositis in hamsters by interleukin-11. Eur. J. Cancer, 31B: 261-266, 1995.
13. Chi, K. H., Chen, C. H., Chan, W. K., Chow, K. C., Shen, S. Y., Yen, S. H., Chao, J. Y., Chang, C. Y., and Chen, K. Y. Effect of granulocyte colony stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil and leucovorin chemotherapy. J. Clin. Oncol., 13: 2620-2628, 1995.
14. Cartee, L., Petros, W. P., Rosner, G. L., Gilbert, C., Moore, S., Affronti, M. L., Hoke, J. A., Hussein, A. M., Ross, M., Rubin, P., Vredenburgh, J. J., and Peters, W. P. Evaluation of GM-CSF mouthwash for prevention of chemotherapy-induced mucositis: a randomized, double-blind, dose-ranging study. Cytokine, 7: 471-477, 1995.
15. Reynoso, E. E., Calderón, E., Miranda, E., Escobar, M. C., de la Geiza, J. G., Ramirez, V., and Sobravilla, P. J. GM-GSF mouthwashes to attenuate severe mucositis after high dose chemotherapy and allogenic bone marrow transplantation or autologous peripheral blood stem cell transplantation. Ann. Oncol., 5 (Suppl. 8): 210-211, 1994.
16. Sonis, S. T., Lindquist, L., Van Vugt, A., Stewart, A. A., Stam, K., Qu, G-Y., Iwata, K. K., and Haley, J. D. Prevention of chemotherapy-induced ulcerative mucositis by transforming growth factor β3. Cancer Res., 54: 1135-1138, 1994.
17. Sonis, S. T., Van Vugt, A. G., O'Brien, J. P., Muska, A. D., Bruskin, A. M., Rose, A., and Haley, J. D. Transforming growth factor β3 mediated modulation of cell cycling and attenuation of 5-fluorouracil induced oral mucositis. Oral Oncol., 33: 47-54, 1997.
18. Strife, A., Lambeck, C., Perez, A., Darzynkiewicz, Z., Skierski, J., Gulati, S., Haley, J. D., ten Dijke, P., Iwata, K. K., and Clarkson, B. D. The effects of transforming growth factor β3 on the growth of highly enriched hematopoietic progenitor cells derived from normal human bone marrow and peripheral blood. Cancer Res., 51: 4828-4836, 1991.
19. Cox, D. A. Transforming growth factor-β3. Cell Biol. Int., 19: 357-371, 1995.
20. Alexandrow, M. G., and Moses, H. L. Transforming growth factor β and cell cycle regulation. Cancer Res., 55: 1452-1457, 1995.
21. Mc Cormack, E. S., Borzillo, G. V., Ambrosino, C., Mak, G., Hamablet, L., Qu, G-Y., and Haley, J. D. Transforming growth factor-β3 protection of epithelial cells from cycle-selective chemotherapy in vitro. Biochem. Pharmacol., 53: 1149-1159, 1997.
22. Wymenga, A. N. M., Van der Graaf, W. T. A., Spijkervet, F. K. L., Timens, W., Timmer-Bosscha, H., Sluiter, W. J., de Vries, E. G. E., and Mulder, N. H. A new assay for quantitation of chemotherapy-induced mucositis. Br. J. Cancer, 76: 1062-1066, 1997.
23. de Vries, E. G. E., ten Vergert, E. M., Mastenbroek, C. G., Dalesio, O., and Rodenhuis, S. Breast cancer studies in the Netherlands. Lancet, 348: 407-408, 1996.
24. WHO. Handbook for Reporting Results of Cancer Treatment, pp. 15-22. Geneva: WHO, 1979.
25. Bioanalytics and Pharmacokinetics, DMPK/BAPK. Development of a Sensitive Immunoassay for the Detection of CGP 46614 (TGF-β3) in Human and Animal Plasma, Report No. BPK(CH) 1997/266. Basel, Switzerland: Novartis Pharma AG, 1997.
26. Drug Metabolism and Pharmacokinetics. A Direct Immuno-assay for the Assessment of Antibody Formation in Human and Animal Plasma after Administration of CGP 46614, Report No. DMPK(CH) 1997/267. Basel, Switzerland: Novartis Pharma AG, 1997.
27. Morelli, D., Ménard, S., Colnaghi, M. I., and Balsari, A. Oral administration of anti-doxorubicin monoclonal antibody prevents chemotherapy-induced gastrointestinal toxicity in mice. Cancer Res., 56: 2082-2085, 1996.
28. Van der Wall, E., Nooijen, W. J., Baars, J. W., Holtkamp, M. J., Schornagel, J. H., Richel, D. J., Rutgers, E. J. T., Slaper-Cortenbach, I. C. M., Van der Schoot, C. E., and Rodenhuis, S. High-dose carboplatin, thiotepa and cyclophosphamide (CTC) with autologous peripheral blood stem cell support in the adjuvant therapy of high-risk breast cancer: a practical approach. Br. J. Cancer, 71: 857-862, 1995.
29. Parulekar, W. Mackenzie, R., Bjarnason, G., and Jordan, R. C. K. Scoring oral mucositis. Oral Oncol., 34: 63-78, 1998.